Add BrightSurf on Google Email

Whole genome or exome sequencing: An individual insight

Research reveals that focusing on coding regions through high-depth coverage whole genome sequencing can accurately identify genetic variations behind CMT, outperforming exome sequencing. Exome sequencing offers greater sensitivity and fewer false positives due to its higher coverage, providing a superior approach for precision medicine.

SourceBMC (BioMed Central)·JournalGenome Medicine·DateJun 26, 2013

Patients should have right to control genomic health information

Bioethicists argue that patients should not be forced to receive genomic information about future health risks without their consent. The ACMG recommendations on reporting incidental findings in clinical genome sequencing are seen as problematic due to concerns over patient autonomy and cost implications.

SourceCell Press·JournalTrends in Biotechnology·DateMay 9, 2013

Newborn baby screening for fragile X syndrome

A large-scale study on newborn screening for fragile X syndrome reveals the high prevalence of the premutation allele among carriers. The research identifies one in 209 females and one in 430 males with the premutation, highlighting the need for better understanding of its impact on families and systems.

SourceBMC (BioMed Central)·JournalGenome Medicine·DateDec 20, 2012

Biomarking time

A study by University of California, San Diego researchers describes markers and a model that quantify how aging occurs at the level of genes and molecules. The findings provide a way to determine a person's actual biological age from just a blood sample.

SourceUniversity of California - San Diego·JournalMolecular Cell·DateNov 21, 2012

Quick and easy diagnosis for mitochondrial disorders

Researchers developed a molecular diagnostic tool that uses targeted genetic sequencing to screen for variations in 362 genes associated with mitochondrial disease. The new method accurately identified the mutation underlying each patient's condition, increasing sensitivity for diagnosing previously unknown genes.

SourceBMC (BioMed Central)·JournalGenome Medicine·DateOct 22, 2009

New gene may provide breast cancer diagnostic marker

A new gene called DEAR1 has been found to be genetically altered in breast tumors and may provide a new prognostic marker for breast cancer patients, particularly those with early-onset cancer. The research suggests that DEAR1-negative staining could help identify young women at high risk of cancer recurrence.

SourcePLOS·JournalPLOS Medicine·DateMay 4, 2009

Genetic clues hold key to schizophrenia treatment

A study by the University of Edinburgh found a gene called DISC1 may control how patients respond to psychiatric medication, offering a potential breakthrough in treating mental illnesses. The research identified seven proteins important to mental illness development, aiming to create new medicines targeting these proteins.

SourceUniversity of Edinburgh·JournalPLOS ONE·DateMar 19, 2009

Prenatal molecular diagnosis for tuberous sclerosis complex

Researchers from Boston University School of Medicine have developed a prenatal testing method for identifying tuberous sclerosis complex (TSC) in the womb. The technique, which sequences TSC genes in amniotic fluid cells, has been shown to detect nearly 93% of mutations, offering improved treatment options for affected families.

SourceBoston University·JournalAmerican Journal of Obstetrics and Gynecology·DateMar 2, 2009